z-logo
Premium
Could pramipexole induce acute mania? A case report
Author(s) -
Bet Pierre M,
Franken Linda GW,
Klumpers Ursula MH
Publication year - 2013
Publication title -
bipolar disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.285
H-Index - 129
eISSN - 1399-5618
pISSN - 1398-5647
DOI - 10.1111/bdi.12067
Subject(s) - pramipexole , olanzapine , mania , bipolar disorder , quetiapine , aripiprazole , medicine , psychology , pharmacology , psychiatry , parkinson's disease , lithium (medication) , schizophrenia (object oriented programming) , disease
Objective In patients with bipolar disorder, olanzapine is commonly used to prevent episodes of acute mania. The drug pramipexole can, in theory, undermine the protective effect of olanzapine. Olanzapine is a dopamine D 2 receptor antagonist and pramipexole is a mixed dopamine D 2 /D 3 receptor agonist. These drugs may therefore theoretically counteract their pharmacological effects. To date, there are no known cases in the literature where this interaction has been described. Methods We report on a case where a patient with bipolar disorder developed mania after taking pramipexole in combination with olanzapine, and describe the pharmacological background of this interaction. Results A patient with bipolar I disorder was hospitalized with a manic episode characterized by agitation and insomnia after taking pramipexole for restless leg syndrome ( RLS ) in combination with olanzapine. Co‐medication, i.e., lithium and mirtazapine, and other circumstances are not likely to have contributed to this effect. Conclusion There is a probable interaction between pramipexole and olanzapine, where pramipexole undermines the protective effect of olanzapine, provoking an episode of acute mania and hospitalization. This interaction is of clinical importance since pramipexole is the treatment of choice for RLS , a condition often seen in end‐stage renal disease, and has also been investigated as an antidepressant therapy in patients with bipolar disorder.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here